Heike Niessner

16PUBLICATIONS
60CO-AUTHORS
Gene and molecular therapyPredictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cardiology (incl. cardiovascular diseases)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Oct 16, 2025
Combinatorial ERK Inhibition Enhances MAPK Pathway Suppression in BRAF-Mutant Melanoma.

Corinna Kosnopfel, Tobias Sinnberg, Shrunal Mane

|Nov 09, 2024
Ecto-NOX Disulfide-Thiol Exchanger 2 (ENOX2/tNOX) Is a Potential Prognostic Marker in Primary Malignant Melanoma and May Serve as a Therapeutic Target.

Matti Böcker, Eftychia Chatziioannou, Heike Niessner

|Dec 09, 2023
Exploring the In Vitro and In Vivo Therapeutic Potential of BRAF and MEK Inhibitor Combination in NRAS-Mutated Melanoma.

Heike Niessner, Anna Hüsch, Corinna Kosnopfel

|Sep 07, 2023
PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction In Vitro and In Vivo.

Lisa Marie Fröhlich, Heike Niessner, Birgit Sauer

|Apr 28, 2023
Relevant Membrane Transport Proteins as Possible Gatekeepers for Effective Pharmacological Ascorbate Treatment in Cancer.

Christian Leischner, Luigi Marongiu, Alban Piotrowsky

|Jan 21, 2023
High-Dose Ascorbate in Combination with Anti-PD1 Checkpoint Inhibition as Treatment Option for Malignant Melanoma.

Markus Burkard, Heike Niessner, Christian Leischner

Pageof 3

Frequent Collaborators

13 joint publications

Tobias Sinnberg

2 joint publications

Claus Garbe

2 joint publications

Corinna Kosnopfel

2 joint publications

Eftychia Chatziioannou